NEJM June 2028 Phase 3 Results of Bepirovirsen Treatment for Chronic Hepatitis B Virus Infection

This text details a medical breakthrough involving bepirovirsen, an innovative antisense oligonucleotide designed to treat chronic hepatitis B. Through two large-scale clinical trials, researchers tested the drug's ability to achieve a functional cure, which allows patients to maintain low viral levels and clear specific antigens even after stopping standard medication. The findings reveal that roughly one-fifth of participants reached this milestone, marking a statistically significant improvement over those receiving a placebo. While the treatment showed promise in suppressing the virus long-term, the study also notes a higher frequency of adverse events among the bepirovirsen group compared to the control group. Ultimately, the source highlights a potential shift in how we manage this lifelong infection by moving toward fixed-duration therapy rather than permanent daily pills.